Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration

May 1, 2024

https://www.globenewswire.com/news-release/2024/05/01/2873175/0/en/Editas-Medicine-and-Bristol-Myers-Squibb-Extend-Alpha-Beta-T-Cell-Collaboration.html

CAMBRIDGE, Mass., May 01, 2024 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq:EDIT), a clinical-stage gene editing company, today announced a two-year extension to the collaboration with Bristol Myers Squibb (NYSE:BMY) under which the parties may research, develop, and commercialize autologous and allogeneic alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The extension also has options to extend the collaboration for up to an additional two years.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.